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Long-term thromboxane-synthase inhibition prolongs survival in mu-
rifle lupus nephritis. Systemic lupus erythematosus (SLE) is an autoim-
mune disease, characterized by nephritis, in which mortality is largely
influenced by the severity of renal involvement. As there are evidences
that thromboxane (TX)A2 plays an important role in the pathogenesis of
lupus nephritis, we decided to assess the effects of long-term suppression
of TXA2 synthesis on the progression of the disease, by designing a study
of TXA-synthase inhibition having adequate size to detect an effect on
mortality as the primary end-point. Thus, we randomized 362 NZBXNZW
mice (11-week-old at entry) to one of the following treatments: a TXA2
synthase inhibitor, FCE 22178 (300 mg/kg daily), saline or cyclophospha-
mide (5 mg/mouse weekly >( 4 weeks) used as reference treatment. The
TXA2 synthase inhibitor suppressed TXA2 biosynthesis, as reflected by
urinary TXB2 and 2,3-dinor-TXB2 excretion (by 78% and 90%, respec-
tively) and significantly reduced mortality (death rate: 34% vs. 61% in
controls, at 37 weeks, P < 0.01). A significant reduction in proteinuria (9
1.6 vs. 17.3 2.4 mg/24 hr in FCE 22178 vs. saline, P < 0.01) and
glomerular lesions was observed up to 30 weeks but not at 37 weeks. In
contrast, cyclophosphamide prevented the development of proteinuria
and histologic lesions, and reduced mortality to 8% at 37 weeks. Renal
plasma flow and glomerular filtration rate were lower (by 29% and 52%,
respectively) in 37-week-old as compared to young NZBxNZW mice.
These parameters were further depressed by cyclophosphamide (by 48%
and 45% vs. age-matched controls, respectively, P < 0.01) but were not
altered significantly by FCE 22178. We conclude that TXA2 biosynthesis
contributes importantly to renal disease progression and mortality of
NZBxNZW mice, though other mechanisms arc likely to be responsible
for proteinuria at later stages.
Glomerulonephritis with progressive renal failure is an impor-
tant cause of morbidity and mortality in patients with systemic
lupus erythematosus (SLE) [1—3].
Many effector systems have been suggested to be involved in the
renal damage of SLE patients [4—6]. In particular, consistent
experimental and clinical data have supported the hypothesis that
intrarenal changes in arachidonate metabolism may contribute to
the pathogenetic mechanisms underlying lupus nephritis. The
most prominent feature of this biochemical abnormality is en-
hanced intrarenal synthesis of thromboxane (TX)A2 [7—9]. Thus,
renal TXA2 production is increased in murine strains, such as the
MRL-lpr/lpr and NZBxNZW Fl hybrid strains, that spontane-
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ously develop an autoimmune disease with nephritis remarkably
similar to human SLE. In these animal models of lupus nephritis,
enhanced renal TXA2 production correlates with both proteinuria
and the development of renal histologic changes. Similar bio-
chemical abnormalities have been described in humans [9, 10].
Within the kidney, TXA2 causes intense vasoconstriction, irre-
versible platelet aggregation, and mesangial cell contraction [11,
12]. Moreover, TXA2 increases extracellular matrix gene expres-
sion [13] and synthesis of matrix proteins [14] and promotes
matrix expansion [13]. Thus, TXA2 acts as a local mediator
possibly amplifying glomerular damage in response to immune
injury. A causal relationship between enhanced TXA2 synthesis,
and functional and structural renal changes have been suggested
by the beneficial effects of short-term prostaglandin (PG)H2/
TXA2 receptor antagonism in both human [15] and animal
models [8, 16] of the disease.
However, it is unknown whether these favorable renal changes
induced by short-term blockade of TXA2 action translate into
long-term benefits, resulting in prolonged survival. Thus, the aim
of the present investigation was to further investigate the patho-
physiologic significance of TXA2 synthesis in murine lupus ne-
phritis by designing a randomized, controlled trial of TXA2
synthase inhibition in NZBxNZW Fl hybrid mice, having mortal-
ity as the primary end point. The sample size and statistical power
were defined in order to detect a moderate effect of such
treatment on survival, as might be expected from elimination of a
single local mediator amplifying glomerular damage in response
to immune injury. Cyclophosphamide was chosen as the reference
treatment, as several studies have shown its efficacy in preventing
renal damage in this murine model of SLE [171.
Methods
Experimental design
Three hundred sixty-two NZBxNZW Fl female mice (Centre
National de la Recherche, Paris, France), 11 weeks of age and
body weight ranging between 25 and 35 g at entry, were random-
ized to one of the following treatments:
(a) FCE 22178 [5,6, dihydro-7-(IH-imidazol-1-yl) 2 naphtalene-
carboxylic acid], a selective TXA2 synthase inhibitor synthesized at
Farmitalia Carlo Erba Research Laboratories [18]. The daily dose
of the drug was 150 mg/kg given orally by gastric tube in the
morning plus 150 mg/kg dissolved in the drinking tap water, The
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concentration of the drug was adjusted weekly according to water
intake in order to maintain the dosage constant throughout the
study. In preliminary experiments, this treatment schedule was
found adequate to maintain over 24 hours greater than 90%
inhibition of platelet TXA2 synthase activity, as assessed by
measurement of whole blood TXB2 production [19].
(b) Cyclophosphamide (Endoxan, Asta-Werke AG, Bielefeld,
Germany) at the dose of 5 mg per mouse, given as a pulse
intraperitoneal injection in saline solution weekly frr four consecutive
weeks. Such a regimen was previously shown effective in reducing
mortality by 40% in the same animal model [20].
(c) Physiological saline, given by oral gavage in the same volume
as for oral treatment with FCE 22178 (0.2 mi/lOg body wt daily). All
animals received a standard chow diet (4RF 21, Mucedola, Milan,
Italy) and had free access to food and water throughout the study.
Treatments were started at twelve weeks of age and continued
until death. The animals also received penicillin (Amplital, C.
Erba, Milan, Italy) given in the drinking water (100 U/ml).
Six animals from each experimental group were sacrified at 30
weeks for histologic studies. Mortality was evaluated weekly
excluding from calculation mice sacrified for histology (N = 18) or
discarded for technical reasons N = 9). All surviving animals
were sacrified at 37 weeks of age for blood analysis, renal
hemodynamic and morphologic studies.
Experimental procedures
Urinaty excretion of proteins. Urine collection was performed at
entry and then at 23, 30, and 37 weeks of age. All animals were
placed in individual metabolic cages with free access to food and
water. After an adaptation period of one day, 24 hour urine was
collected into refrigerated containers. Total urinary protein con-
centration was measured by the Biuret method (Total protein,
Boehringer Mannheim, Mannheim, Germany) and the excretion
rate expressed as mg124 hr. Samples were frozen and stored at
—80°C until assayed for POE2 and TXA2 metabolites.
Blood analysis. Twenty-four hours after the last treatment,
blood samples were obtained under halothane anesthesia from
the abdominal aorta, under fed conditions. All mice alive at 37
weeks except those selected for hemodynamic studies were sam-
pled for measurement of whole blood TXB2 production (1 hr at
37°C) as previously described [19].
Extraction and chromatographic separation of urinary eico-
sanoids. In order to assess the extent of TX-synthase inhibition in
vivo, we measured the urinary excretion of TXB2, the chemically
stable hydration product of TXA2, and 2,3-dinor-TXB2, a major
enzymatic metabolite of TXB2 [21, 22]. We used previously
described methods [9] with few modifications. Briefly, urine
samples were acidified to pH 3.5 with formic acid and then
applied to Sep-Pak C18 columns (Waters Associates, Milford,
MA, USA) pretreated with 10 ml methanol and 10 ml water. The
columns were then eluted with 10 ml water, 10 ml n-exane, and 10
ml ethyl acetate. The ethyl acetate fraction was evaporated to
dryness in a rotary evaporator at 37°C (Buehler vortex evaporator,
Sedas Analitica, Milan, Italy). Silicic acid (0.65 g) was suspended
in 4 ml of benzene/ethyl acetate (60:40; solvent 1), and added to
a small glass column (6 X 0.7 cm). The column was washed with
4 ml of benzene/ethyl acetate/methanol (60:40:30; solvent 2) and
5 ml of solvent 1. The extracted residue was dissolved in 0.2 ml of
benzene/ethyl acetate/methanol (60:40:10) and 0.8 ml of solvent 1.
The mixture was applied to the column and eluted with 5 ml of
solvent 1 (fraction 1) and 10 ml of solvent 2 (fraction 2). This
fraction was collected and taken to dryness at 37°C, redissolved in
150 1id water/methanol (2:1) for HPLC analysis. TXA2 metabo-
lites were separated by a Waters HPLC system, Model 510, using
a Nova Pak C 18 column (Waters) with 0.14% acetic acid/
acetonitrile solution (74:26) as mobile phase at the flow rate of 1.0
ml per mm. Specific eluate fractions were collected based on
authentic TXB2 and 2,3-dinor-TXB2 retention times as deter-
mined spectrophotometrically (210 nm). All measurements were
corrected for recovery of tritiated standards added to each urine
sample. Urinary PGE2 was extracted and measured by radioim-
munoassay, as previously described [9].
Radioimmunoassays. The concentrations of TXB2 in serum
samples, and of TXB2, 2,3-dinor-TXB2 and PGE2 in HPLC
fractions or extracted urine, were determined by previously vali-
dated radioimmunoassays [9, 19]. Briefly, 6,000 dpm of 3H-TXB2
(114 Ci/mmol), or 3F1-PGE2 (186 Ci/mmol) and appropriate
amounts of specific antisera (final dilution for TXB2 antiserum
1:250,000; for 2,3-dinor-TXB2 and POE2 antisera 1:80,000) suffi-
cient to bound 40 to 50% of the corresponding tracer, were
incubated for 24 hours at 4°C in a final volume of 1.5 ml.
Separation of antibody-bound from free labeled eicosanoids was
achieved by rapid addition of 0.1 ml of 5% albumin and 0.05 ml of
a charcoal suspension (500 mg/mI) and subsequent centrifugation
at 4°C. Supernatant solutions containing antibody-bound eico-
sanoids were decanted directly into 10 ml Instagel (Packard
Instrument Co. Inc., Downers Grove, IL, USA). The radioactivity
of samples was counted in a liquid scintillator counter (model LS
1800, Beckman Instruments, Irvine, CA, USA). The smallest
concentration that could he measured with 95% confidence was 2
pg/mI for all eicosanoids.
Renal hemodynamic studies. Renal function was evaluated in
mice by inulin and p-amino-hippuric acid (PAR) clearances using
the procedure adapted from rats, previously described by Spurney
et al [8]. Inulin and PAR clearances were measured in young
NZBxNZW mice (11 weeks of age, N = 6) and in 37-week-old
NZBxNZW belonging to the three different experimental groups
(N = 5 to 6 per group). Due to the low proteinuria in the
cyclophosphamide group, animals were selected for hemodynamic
studies on the basis of comparably low levels of urinary protein
excretion: 3.9 0.8, 3.2 0.7 and 3.1 0.9 mg/24 hr in saline-,
FCE 22178- and cyclophosphamide-treated mice, respectively.
Eleven-week-old Swiss mice (N = 5; C. River, Calco, Italy) were
also studied as young healthy controls (proteinuria: 1.8 0.3 mg/
24 hr). Briefly, on the day of the study, animals were anesthetized
with sodium pentobarbital, 0.04 mg/g body weight. After a trache-
ostomy, the left jugular vein and left carotid artery were cannu-
lated with polyethylene catheters (PE 10; Clay Adams, Parsip-
pany, NJ, USA) to allow intravenous infusions and to monitor the
mean arterial pressure on a R511A recorder (Beckman Instru-
ments Inc., Irvine, CA, USA) as well as to allow sampling of
arterial blood. In order to collect urine samples, the bladder was
cannulated with a PE 50 catheter, via a suprapubic incision. To
adequately replace surgically-induced volume losses, intravenous
administration of normal saline solution (2% of body wt) was
performed over 20 minutes.
A priming dose of carboxyl-'4C-inulin (5 j.Ci/kg) and glycyl-
3H-PAH (10 iCi/kg; New England Nuclear, Boston, MA, USA)
was given followed by a continuous infusion of 14C-inulin and
3H-PAH to maintain constant blood levels (0.2 and 1 sCi/kg/min,
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Table 1. Urine volume (m1124 hr) in NZBXNZW mice according to
assigned treatment and age at measurement
Treatment
Weeks of age
11 23 30 37
Saline 1.2 0.5 1.3 0.6 1.3 0.8 1.2 0.8
N 112 104 86 39
FCE 22178 1.3 0.7 1.4 0.5 1.2 0.7 1.2 0.7
N 122 104 94 71
CPA 1.3 0.6 1.3 0.5 1.0 0.4a 0.7 0.5
N 105 105 98 81
Abbreviation is CPA, cyclophosphamide. Data are means SD. Treat-
ments were performed as reported in the text; N is the number of animals.
a P < 0.01 vs. age-matched saline-treated controls by Duncan's test
respectively, in normal saline). After a 30-minute equilibration
period, clearances of inulin and PAH were determined during
three consecutive 30-minute urine collections. Arterial blood
samples (50 pJ) were drawn coincidently with the midpoint of
each urine collection. Carboxyl-14C-inulin, and glycyl-3H-PAH in
plasma and urine were measured with a dual channel liquid
scintillation counter (Tri-Carb 1900CA, Packard Instrument
Company Inc.) and clearances were calculated using standard
formulas [8]. For each animal, values determined during the three
clearance periods were averaged and means used for statistical
analysis.
Histologic studies. Six animals from each experimental group
were sacrified at 30 weeks and 12 animals at 37 weeks of age. Part
of the renal tissue was fixed in 10% buffered formalin for 24 to 48
hours; paraffin sections (6 m) were stained with hematoxylin-
eosin and periodic acid-Schiff (PAS) and examined by light
microscopy by two observers blinded to the nature of treatment.
Histologic changes were classified into six classes according to the
World Health Organization (WHO) criteria of classification of
human lupus nephritis, modified by the International Study of
Kidney Disease in Children (ISKD) [23, 241. Semiquantitative
evaluation of renal damage was obtained by scoring acute glomer-
ulonephritis (GN), glomerulosclerosis (GS), and interstitial dam-
age (IN) from 0 to 4, based on the severity of lesions according to
Passwell et al [25]. Indices of disease activity (AT) and chronicity
(CI) were evaluated using the scoring systems reported by Baldi et
al [26] in mouse SLE and by Austin Ct al in human lupus nephritis
[27].
Immunofluorescence studies. Pronase (Sigma) digested paraffin
sections (6 /.tm) from four animals for each group (37 weeks of
age) were used for immunofluorescent staining with fluorescein-
conjugated rabbit antisera specific for mouse immunoglubulins,
diluted 1:50 (Dakopatts, Glostrup, Denmark).
Statistical analysis
Data in the text are expressed as means SD. Data were
analyzed by analysis of variance followed by Duncan's test for
multiple comparisons [28]. The sample size was calculated in
order to detect a difference in mortality rate between groups of at
least 20%, with a Type 1 error (a) of 0.05, and a power (1-/3) of
0.90 [291. Mortality rates were compared with the Kaplan-Meier
test [30] followed by the Log-rank test [311.
The Al and CI values were analyzed by analysis [28].
Results
Urine volume and total protein excretion
Urine volume and protein excretion were comparable in the
three groups at the beginning of the study. In control, saline-
Table 2. Urinary protein excretion (mg/24 hr) in NZBxNZW mice
according to assigned treatment and age at measurement
Treatment
Weeks of age
11 23 30 37
Saline 7.4 2.7 7.1 5.8 17.3 22.5 20.3 26.0
N 112 104 86 39
FCE 22178 8.4 3.5 6.9 3.8 9.3 15.5a 21.4 23.8
N 122 104 94 71
CPA 7.7 3.1 7.7 3.8 2.6 1.4 5.2 6.2a
N 105 105 98 81
Abbreviation is CPA, cyclophosphamide. Data are means SD. Treat-
ments were performed as reported in the text; N is the number of animals.
P < 0.01 vs. age-matched saline-treated controls by Duncan's test
treated NZBxNZW mice, urine volume (Table 1) remained
constant throughout the observation period, yet marked protein-
uria developed after the 23rd week of age (Table 2). TXA2
synthase inhibition significantly reduced proteinuria at 30 weeks
(9.3 15.5 vs. 17.3 22.5 mg/24 hr in controls, P < 0.01), but this
effect was no longer detectable at 37 weeks (Table 2). Urine
volume was not affected by treatment. In the cyclophosphamide-
treated group the development of proteinuria was totally pre-
vented. A lower urine volume was measured concomitantly with
lower protein excretion (Table 1).
Eicosanoid measurements
The TXA2 synthase inhibitor, FCE 22178, caused inhibition of
whole blood TXB2 production by approximately 90% as com-
pared to values in control mice, based on samples drawn 24 hours
after treatment (7.8 9.4 vs. 81.1 41.7 ng/ml, P < 0.01, at 37
weeks of age). Cyclophosphamide did not affect serum TXB2
(89.8 42.5 ng/ml) to any statistically significant extent (data not
shown).
In control, saline-treated NZBxNZW mice, a statistically sig-
nificant (P < 0.01) increase in both urinary TXB2 and 2,3-dinor-
TXB2 was measured at 37 weeks (Fig. 1). In both young (11 weeks
of age) and old (37 weeks of age) control animals, the excretion
rate of TXB2 was less than 10% of that of 2,3-dinor-TXB2.
PGE2 excretion was modestly, yet significantly, enhanced in
37-week-old controls (Fig. 1). TXA2 synthase inhibition signifi-
cantly (P < 0.01) reduced both TXB2 and 2,3-dinor-TXB2 excre-
tion by 95% and 78%, respectively, at 37 weeks without modifying
the urinary excretion of PGE2, as compared to age-matched
controls.
Renal hemodynamic studies
Glomerular filtration rate (GFR), as measured by 14C-inulin
clearance, renal plasma flow (RPF), as measured by 3H-PAH
clearance, and filtration fraction (% FF) in young NZBXNZW
mice were not significantly different from those measured in
age-matched Swiss mice. Renal function decreased to a compa-
rable extent in 37-week-old NZBXNZW mice exposed to either
saline or FCE 22178 (Table 3). However, the selection criteria of
matching mice on the basis of low levels of urinary protein
excretion, may have significantly biased the results by either (1)
selecting animals with mild renal disease, or (2) selecting animals
with significant impairment of renal hemodynamic function and
thus low levels of proteinuria. Either of these possibilities may
account for the failure to detect a difference in renal hemody-
namic function between the saline-treated and FCE 22178-treated
groups. This potential limitation of the results has to be taken into
Salvati et al: TXA2 synthase inhibition in murine lupus 1171
Treatment N
Age
weeks
GFR RPF FF
%mi/mm/kg
Saline
Saline
FCE 22178
CPA
6
5
6
5
11
37
37
37
19.9 9.3
9•5 40b
11.5 5Q
5.3 27b
34.8 15.5
24.9 4.6
27.6 7.8
13.1 37b
57.1 4.5
37.8 12.&'
41.0 10.5k
38.7 11.4l
Abbreviations are: GFR, glomerular filtration rate; RPF, renal plasma
flow; FF, filtration fraction; CPA, cyclophosphamide. Values are means
so of (N) animals. Control values in 11-week-old Swiss mice are GFR, 20.8
1.8 ml/min/kg; RPF, 45.4 3.9 mI/mm/kg; FF, 46 4%.
a < 0.05, bP < 0.01 vs. 11-week-old NZBXNZW mice by Duncan's test
consideration, however, a random selection might have intro-
duced an even greater bias, due to the wide distribution of
proteinuria values in controls and FCE 22178-treated mice, but
not in the cyclophosphamide group. Interestingly, a more pro-
nounced fall in renal hemodynamics was found in cyclophospha-
mide-treated animals despite the adopted selection criteria.
Renal histologic studies
By light microscopy (Fig. 2), five out of six examined 30-week-
old control NZBXNZW mice showed diffuse endocapilary gb-
merulonephritis. Active lesions were present in three animals; in
one of these, cellular crescents were also observed. Focal mesan-
gioproliferative lesions were seen in one animal. Segmental
glomerulosclerosis was observed in three out of six mice. At 37
weeks of age, six out of 12 saline-treated NZBxNZW mice
presented severe diffuse mesangioproliferative glomerulonephri-
tis; diffuse proliferative endocapillary glomerulonephritis with
additional cellular crescents characterized the remaining animals.
Sclerotic lesions of variable severity were also observed in the
eight of these 12 mice. FCE 22178-treated 30-week-old NZBx-
NZW mice did not show relevant glomerular lesions. However,
diffuse endocapillary glomerulonephritis was observed in one
animal. At 37 weeks of age mesangial (4 out of 12) and endocap-
illary (5 out of 12) proliferative glomerulonephritis was present in
two thirds of FCE 22178-treated animals. Active lesions were seen
in four mice. An equal number of animals (4 out of 12) presented
mild sclerosing lesions. The frequency of low and high scores for
specific histologic abnormalities are reported in Tables 4 and 5.
Similar results were obtained by using the method of Passwell et
al [25] for scoring glomerular lesions, or Al and CI as previously
used by Baldi et al in murine SLE [26]. When frequency distri-
bution of renal pathology was performed according to the cut-off
points reported by Austin et al [27], as indicative for high risk of
end-stage renal disease in humans, a statistically significant dif-
ference in the severity of lesions between FCE 22178-treated and
saline-treated animals of this age-group became apparent. On the
other hand, cyclophosphamide treatment prevented the occur-
rence of renal lesions at both experimental time points.
Immunoflurescence studies
Moderate or intense immunofluorescent staining for immuno-
glubulins was observed in saline- and FCE 22178-treated animals
with mesangioproliferative or diffuse endocapillaty glomerulone-
phritis. Little or no staining was seen in cyclophosphamide- and in
FCE 22178-treated mice with minimal or no histological lesions
(data not shown).
A
*
*
*
*
Table 3. Renal hemodynamics in NZBxNZW mice, according to
assigned treatment and age at measurement
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Fig. 1. Urina,y excretion of (A) 2,3-dinor-TXB2, (B) IXB2, and (C) PGE2
measured in control NZBxNZW mice at 11 weeks of age (, N = 12),
saline-treated (, N = 8) and FCE 22178-treated (, N 5) NZBxNZW
mice at 37 weeks of age. Data are means SEM. ** P < 0.01 versus
37-week-old saline-treated control mice by analysis of variance and
Duncan's test.
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Fig. 2. Renal histology of NZBxNZW mice associated with different treatments. Most of the control NZBxNZW mice, at 30 (a) and 37 (b) weeks of age,
showed diffuse endocapillaiy glomerulonephritis, with "active" lesions in half of the animals. FCE 22178-treated, 30-week-old NZBxNZW mice did not
demonstrate relevant glomerular lesions (c), while diffuse proliferative glomerulonephritis (d) was present in two thirds of the FCE treated animals, at
37 weeks of age. Treatment with cyclophosphamide prevented the appearance of renal lesions at both 30 (e) and 37 (f) weeks of age. H&E. X 175.
Effect of treatments on survival weeks of age; by 37 weeks, 70 animals (6 1%) were dead (Fig. 3).
In saline-treated NZBXNZW mice (N = 114 considered for TXA2 synthase inhibition significantly (P < 0.01) prolonged survival
calculation), the death rate increased dramatically from 26 to 28 in NZBXNZW, as only 40 (34%) of the FCE 22178-treated mice
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Tal.jIe 4. Frqueney of ON, Os and IN scores in NZBxNZW mice at
30 ajsd 37 weeks of age, accOrding to assigned treatment
Age
w,:eks N Treatment
GN
<1 >1
GS
0>0
IN
0 >0
30 6
6
6
Vehicle
FCE 22178
CPA
1
5'
6"
5
I
0
3
6"
6"
3
0
0
4
6
6
2
0
07 12
12
12
Vehicle
FCE 22178
CPA
0
3
11h
12
9
1
4
7
12b
8
5
0
6
8
12"
6
4
0
Abbreviations are: GN, glomerulonephritis; OS, glomeruloscierosis; IN,
inrerstitial nephritis; cut-off points according to [25]; CPA, cyclophosph-
amide.
P <.0.05, b P < 0.01 vs. vehicle by x2 test
(N = 116) were dead at 37 weeks of age. The difference with respect
to the control group became statistically significant at 30 weeks of age
and remained so throughout the study (Fig. 3).
CyclophospFiamide treatment markedly improved survival.
Thus, of the 105 mice included in the calculation, 97(92%) were
still alive at the end of the study (Fig. 3).
Discussion
The present study demonstrates that long-term TXA2 synthase
inhibition prolongs survival in a murine model of lupus nephritis.
The pathophysiologic role of TXA2 in mediating inflammatosy
events and renal function deterioration in experimental lupus
nephritis has been investigated previously [7—10]. Dietary manip-
ulations possibly leading to decresed TXA2 synthesis, such as fish
oil-enriched diets [32—341? or essential fatty acid-deficient diet
[351, have been shown to reduce the progression of nephritis and
prolong survival in murine lupus. However, the contribution of
reduced TXA2 production to these effects is difficult to dissect out
from more complex changes in arachidonate metabolism through
the cyclooxygenase and 5-lipoxygenase [36] pathways. Moreover,
these dietary manipulations are associated with biochemical
changes unrelated to eicosanoid production [32, 35].
Selective PGH2/TXA2 receptor blockade has been reported to
slow the progression of lupus nephritis, in MIL-lprI1pr mice [16],
and ameliorate renal hemodynamics in SLE patients [15]. The
available data on PGH2TI'XA2 receptor antagonism, however,
leave the question unanswered as to whether this phariacologic
intervention can prolong survival in lupus nephritis.
The present study of selective TXA2 synthase inhibition in
N'ZPxNZW mice was designed with mortality as the primary
end-point, and had adequate sample size to detect a moderate
(20%) reduction in death rate, as might realistically be expected
from such selective mediator suppression.
Our biochemical measurements confirm previous findings of
enhanced TXA2 biosynthesis in NZBXNZW mice, as reflected by
increased urinary TXB2 and 2,3-dinor-TXB2 excretion at 37
weeks of age. It has been suggested that urinary excretion of
2,3-dinor-TXB2 reflects extrarenal TXA2 production, largely de-
rived from platelets in humans [12, 37, 38]. However, recent
studies have shown that /3-oxidation of TXB2 can also occur within
the rat kidney [22]. While some evidence exists in humans to
suggest that urinary excretion of unmetabolized TXB2 reflects the
intrarenal production of TXA2 [9, 15], no information is available
Table 5. Frequency of acuity, and chronicity indexes in NZBxNZW
mice at 30 and 37 weeks of age, according to assigned treatment
Age Acuity" Chronicity" Activityt' Chronicity"
weeks N Treatement 4 >4 0 >0 <12 12 <1 >1
30 6 Vehicle 1 5 3 3 5 1 6 0
6 FCE 22178 5' 1 6C 0 6 0 6 0
6 CPA 6" 0 6" 0 6 0 6 0
37 12 Vehicle 4 8 4 8 6 6 7 5
12 FCE 22178 5 7 8 4 11 1 12" 0
12 CPA 12d 0 12" 0 12" 0 12" 0
"Cut off points according to [26]
"Cut off points according to [27]
Abbreviation is CPA, cyclophosphamide.
"P < 0.05, "P < 0.001 vs. vehicle by x2 test
on the metabolic disposition of TXB2 in mice. In the present study
we found that the excretion rate of 2,3-dinor-TXB2 in young
NZBXNZW mice was about tenfold higher than that of TXB2.
The urinary excretion of both metabolites was markedly enhanced
in association with full expression of renal disease at 37 weeks in
control animals. Whether increased TXA2 biosynthesis involved
only renal resident and infiltrating cells or also circulating plate-
lets remains unanswered by the present study.
The selective TXA2 synthase inhibitor, FCE 22178, given at a
dose causing greater than 90% inhibition of platelet TXB2
production er vivo, largely suppressed TXA2 biosynthesis in vivo
with no effect of PGE2 excretion (Fig. 1).
Treatment with FCE 22178 also prevented the increase in
proteinuria and the appearance of glomerular lesions, detected at
30 weeks of age in control animals (Table 2 and Fig. 2). A diffuse
glomerulonephritis occurred in most FCE 22178-treated mice at
37 weeks of age, with less severe signs of acuity and chronicity
than in control animals, thus suggesting a beneficial effect of
treatment on renal disease progression, despite comparable levels
of proteiiluria in both groups. Light microscopy data were con-
firmed by immunoflurescence studies.
The present demonstration that long-term inhibition of TXA2
synthesis can reduce mortality contrasts with the lack of beneficial
effects of TXA2 synthase inhibition on survival of NZBXNZW
mice in a previous study [39]. Inadequate sample size (20 mice per
group) as well as incomplete inhibition of renal TXA2 production
(as reflected by a 40% reduction in urinary TXB2 excretion) can
probably account for the negative findings of Clark et al [39]. A
previous study of PGH-synthase inhibition, sufficient to reduce
platelet cyclooxygenase activity by 90%, also failed to improve
survival in NZBXNZW mice; however, renal TXB2 synthesis was
unaffected by the inhibitor [7], thus indirectly suggesting the
importance of inhibiting the intrarenal production of this eico-
sanoid.
Immunosuppression prevented the development of the disease,
as both proteinuria and morphologic changes were suppressed by
cyclophosphamide. At variance with previous studies of cyclo-
phosphamide showing partial protection [20], we found that the
pulse dose of 5 mg/mice per week for four consecutive weeks, was
sufficient to completely prevent the development of lupus nephri-
tis in this strain of mice. Notably, cyclophosphamide appeared to
further depress renal function reducing RPF and GFR in old
NZBxNZW mice. This effect might contribute, at least in part, to
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Further testing of this hypothesis with structurally unrelated
synthesis inhibitors and/or receptor antagonists might help defin-
ing the cellular target(s) and molecular mechanism(s) of the
beneficial effects of TXA2 inhibition and set the stage for clinical
trials of these agents in lupus nephritis.
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